MedTrace Logo

Amniotic Fluid Ischemia Modified Albumin as a Novel e Prenatal Diagnostic Marker for Down Syndrome

NCT04293380 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2020-12-17

No results posted yet for this study

Summary

Down syndrome is the most common genetic disorder in the society that causes mental retardation. Today, screening tests (combined test, triple screening, ultrasonography and age) are performed for the diagnosis of down syndrome for all pregnant women. As a result of screening tests, amniocentesis is performed as a diagnostic test for the group at risk. Chromosome analysis from amniotic fluid requires a 3-week period for chromosome cultures to yield results. Several levels of biochemical markers, such as organic acids and pyridoxine metabolites, have been found to be elevated in the amniotic fluid. The investigators also plan to investigate ischemia-modified albumin, hepatocyte growth factor level in amniotic fluid.

Conditions

  • Down Syndrome
  • Prenatal Stress
  • Cytokines

Interventions

PROCEDURE

amniosyntesis

Sponsors & Collaborators

  • Karadeniz Technical University

    lead OTHER

Principal Investigators

  • suleyman guven, professor · karadeniz thecnical universty

  • erhan huseyın comert · gole goverment hospital

  • emine seda guvendag guven · karadeniz thecnical universty

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
CROSSOVER

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-01
Primary Completion
2016-06-01
Completion
2016-09-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04293380 on ClinicalTrials.gov